Abstract
Background: Several commercial drugs utilized in the treatment of HSV containing pyrimidine moiety. Because of the ineffectiveness of virus drugs due to the resistance of the patient's immune system, there is a pressing need to prepare new compounds that are effective in the treatment of various viruses.
Results: Merged pyrimidine derivatives were designed by one pot synthesis of pyrimidinethione derivative with halogenated compounds. The structure of all prepared compounds was characterized by their spectroscopic data and also, their ability to inhibit the in vitro replication of HSV-1 was estimated. Amongst the tested compounds 2-acety1-3-methy1-5-(p-toly)indeno [1,2-d]thiazolo [3,2a]pyrimidin -6(5H)-one (9b) and ethyl 3-methy1-6-oxo-5-(p-tolyl)-5,6-dihydroindeno [1,2-d]thiazolo[3,2-a]pyrimidine-2-carboxylate (9c), caused viral inhibition over 90%. Furthermore, the selectivity indices of the tested compounds are high and have weak cytotoxicity (all samples were checked, not chosen on cytotoxicity basis, we only utilize secure concentrations of every compound).
Conclusion: We succeeded in this context to synthesize a new series of potent fused pyrimidine derivatives as anti-HSV-1.